The objective of the planned study is to demonstrate if ETVAX®, given with two doses 14 days apart and a booster dose at day 90, is safe and provides protection against moderate-to-severe diarrhoea caused by ETEC. The study is a randomized, placebo-controlled, double-blind, field trial of the vaccine in approximately 5000 children residing in an ETEC-endemic area in The Gambia.

This study is co funded by  the EU Research and Innovation Framework Program, Horizon 2020 through the European and Developing Countries Clinical Trials Partnership (EDCTP) organization.